Aristotle University Of Thessaloniki (AUTH)
Ανίχνευση πρώιμης μυοκαρδιακής δυσλειτουργίας σε παιδιά και εφήβους με κοιλιοκάκη: επίδραση της δίαιτας χωρίς γλουτένη και συσχέτισή της με νέους βιοδείκτες Fatty Acid-Binding Protein-I & Fatty Acid-Binding Protein-H
Abstract
dc:descriptionIntroduction: Celiac disease is a chronic autoimmune enteropathy of the small intestine affecting genetically predisposed individuals upon dietary gluten exposure, and has been recognized as a systemic disorder. Treatment relies on strict adherence to a gluten-free diet (GFD), with anti-tissue transglutaminase IgA antibodies (anti-tTG IgA) serving as the established serological marker of dietary compliance. Its systemic nature, combined with its autoimmune background, support the hypothesis of cardiac involvement. Fatty acid-binding proteins (FABPs) are a family of proteins primarily involved in the regulation of long-chain fatty acid uptake and intracellular transport. In patients with celiac disease, the intestinal isoform (I-FABP) correlates with the severity of intestinal damage. The cardiac isoform (H-FABP) is a marker of myocardial injury, but it has not been systematically evaluated in this specific condition. Aim: The aim of the present study was to compare myocardial function in children and adolescents with celiac disease and healthy controls, using conventional and advanced echocardiographic imaging techiques (TDI), to investigate the effect of a GFD on cardiac function in a prospective follow-up, and to evaluate I-FABP and H-FABP as complementary biomarkers of intestinal and potential subclinical myocardial involvement, respectively.Methods: A total of 262 children and adolescents participated in the study: 142 with biopsy-proven celiac disease and 120 healthy controls. At enrollment (cross-sectional study), patients were categorized according to gluten-free diet (GFD) adherence using a 6-month threshold (noGFD/GFD<6m: n=57 vs GFD≥6m: n=85), anti-tTG IgA antibody levels (negative: n=55, borderline: n=13, positive: n=74), and clinical presentation at diagnosis (typical: n=48, atypical: n=76 and silent: n=18). All participants underwent full clinical assessment, electrocardiography, transthoracic echocardiography and laboratory evaluation. In controls, laboratory workup included full blood count, basic biochemistry, lipid profile and anti-tTG IgA to exclude subclinical celiac disease. In patients, additional disease-related parameters, including nutritional indices, anti-tTG IgA titre, full lipid profile, and I-FABP (n=141) and H-FABP (n=140) levels were recorded. Patients with positive or borderline anti-tTG IgA at enrollment formed the prospective follow-up cohort (n=87, 242 visits), in which diet status was assessed independently of the 6-month threshold (newly diagnosed vs already on GFD). Serological response was defined at two levels: active phase (positive or borderline anti-tTG IgA) versus serological remission (negative anti-tTG IgA). Statistical analysis included multivariable linear regression and linear mixed models adjusted for age, sex and BMI z-score, as well as paired t-test in 49 patients with echocardiography in both phases (positive/borderline vs negative anti-tTG IgA). Results: In the cross-sectional analysis, subclinical myocardial dysfunction was observed in the 142 celiac patients compared to 120 healthy controls. The Myocardial Performance Index (MPI) was increased at both the septal (β=0.385, p<0.001) and lateral (β=0.378, p<0.001) mitral annulus. Ejection fraction (EF) and fractional shortening (FS), although remaining within normal ranges, were lower in the patient group (β=-2.394 and β=-1.757 respectively, p<0.01). The E/e’ ratio at both septal (β=1.356, p<0.001) and lateral (β=1.202, p<0.001) sites was elevated, indicative of diastolic dysfunction. Longitudinal systolic function indices (MAPSE, TAPSE), left ventricular mass and dimensions did not differ significantly. All three anti-tTG IgA subgroups (negative n=55, borderline n=13, positive n=74) differed significantly from controls, but not from each other after multivariable adjustment, with a significant linear trend of TDI parameters deterioration with increasing antibody burden, including controls (p trend <0.01). In the longitudinal analysis, 87 patients were followed over 242 visits. Serological remission under GFD led to significant improvement in MPI, E/e’, IVRT, IVCT and ET. In a subgroup analysis of 49 patients with echocardiography during both phases (paired sample), a significant improvement of the same indices was confirmed. Despite significant improvement, both the comparison of 50 patients with negative anti-tTG IgA against 120 healthy controls (multivariable analysis) and the comparison of 49 patients in remission with age- and sex-matched healthy controls demonstrated that TDI parameters remained significantly impaired (all p<0.02). I-FABP levels were significantly higher in newly diagnosed patients, compared to those on GFD (median: 0.54 vs 0.29 ng/mL, p=0.002), while neither I-FABP nor H-FABP showed a significant correlation with echocardiographic indices or serological status. However, a moderate positive correlation was observed between I-FABP and H-FABP (rho=0.45, β=0.70, p<0.001), suggesting that patients with higher intestinal injury tend to simultaneously exhibit higher myocardial injury. Conclusions: Children and adolescents with celiac disease exhibit subclinical myocardial dysfunction, detectable mainly through advanced imaging (TDI), which improves after anti-tTG IgA become negative, but does not fully return to the levels observed in healthy population. Although GFD remains the only treatment, early cardiac assessment for these patients would be advisable, with the aim of identifying and managing modifiable cardiovascular risk factors, in conjunction with appropriate dietary guidance.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Emmanouilidou-Fotoulaki, Elpida
- Εμμανουηλίδου-Φωτουλάκη, Ελπίδα
Subjects
dc:subject × 16- Κοιλιοκάκη
- Παιδιά και έφηβοι
- Μυοκαρδιακή δυσλειτουργία
- Fatty Acid-binding Protein 2
- Fatty Acid-binding Protein 3
- Αντισώματα έναντι ιστικής τρανσγλουταμινάσης
- Celiac disease
- Children and adolescents
- Myocardial dysfunction
- Anti-tissue transglutaminase antibodies
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Παιδιατρική, Νεογνολογία και Υγεία του παιδιού
- Clinical Medicine
- Medical and Health Sciences
- Pediatrics, Perinatology and Child Health
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/63043